Enanta Pharmaceuticals (ENTA) Depreciation & Amortization (CF) (2012 - 2026)

Enanta Pharmaceuticals' Depreciation & Amortization (CF) history runs 15 years deep, the most recent figure standing at $1.2 million for Q1 2026.

• Quarterly Depreciation & Amortization (CF) changed 0.5% year-over-year to $1.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $4.9 million (up 55.86% YoY) and the FY2025 annual result came in at $4.6 million, up 96.32% from the prior year.
• Depreciation & Amortization (CF) was $1.2 million for Q1 2026 at Enanta Pharmaceuticals, down from $1.2 million in the prior quarter.
• Across five years, Depreciation & Amortization (CF) topped out at $1.3 million in Q3 2025 and bottomed at $479000.0 in Q3 2024.
• A 5-year average of $819117.6 and a median of $669000.0 in 2023 frame the typical range for Depreciation & Amortization (CF).
• Annual changes were most pronounced in 2022 — Depreciation & Amortization (CF) plunged 34.49% — and 2025, when it jumped 168.06%.
• Enanta Pharmaceuticals' Depreciation & Amortization (CF) stood at $511000.0 in 2022, then climbed by 25.64% to $642000.0 in 2023, then jumped by 38.47% to $889000.0 in 2024, then surged by 38.36% to $1.2 million in 2025, then decreased by 1.71% to $1.2 million in 2026.
• Business Quant data shows ENTA's Depreciation & Amortization (CF) at $1.2 million in Q1 2026, $1.2 million in Q4 2025, and $1.3 million in Q3 2025.